Another novel anti-EGFR antibody, mAb 806, is active against cell lines expressing the mutant variant EGFRvIII as well as cell lines in which wild type EGFR is over-expressed.48 Cetuximab, nimotuzumab, panitumumab and matuzumab all prevent ligand binding via interactions with EGFR domain III, and mAb 806 interferes with receptor function via interactions with domain II.4952 The clinical significance of these molecular interactions of antibody and receptor is unknown and is the subject of ongoing basic research.
|